Denali therapeutics announces robust reduction in neurofilament light (nfl) with dnl310 (etv:ids) treatment in mps ii (hunter syndrome)

South san francisco, calif., june 20, 2023 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim results from the ongoing open-label, single-arm phase 1/2 study of dnl310 (etv:ids) in children with mps ii (hunter syndrome). among the 13 participants who reached two years of treatment at the time of the interim analysis, a mean reduction of 64% (p
DNLI Ratings Summary
DNLI Quant Ranking